Benzinga · Feb 19, 2026
D. Boral Capital Downgrades Geovax Labs to Hold
D. Boral Capital analyst Jason Kolbert downgrades Geovax Labs (NASDAQ:GOVX) from Buy to Hold.
GO
NASDAQ · GOVX
GeoVax Labs, Inc. New
Healthcare · Biotechnology
$0.46
Down-$0.02 (-4.99%)
Updated Sep 14, 2026, 4:13 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.64M
- P/E ratio
- -0.3
- Dividend yield
- 0.00%
- 52-week range
- $0.45 – $18.20
- Volume
- 126.48K
- Avg. volume
- 794.22K
Price performance
GOVX price history
1M range · 19 trading sessions · Daily adjusted prices
GOVX closed at $0.46 after 19 trading sessions, down 29.31% for the selected period.
- Last close
- $0.46
- Period change
- -29.31%
- Period low
- $0.46
- Period high
- $0.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.48 | $0.4894 | $0.45 | $0.463 | 126.48K |
| Sep 10, 2026 | $0.49 | $0.49 | $0.4602 | $0.4655 | 316.39K |
| Sep 9, 2026 | $0.48 | $0.4885 | $0.4499 | $0.4688 | 337.85K |
| Sep 8, 2026 | $0.50 | $0.50 | $0.46 | $0.468 | 514.63K |
| Sep 4, 2026 | $0.53 | $0.53 | $0.48 | $0.4831 | 550.73K |
| Sep 3, 2026 | $0.5525 | $0.5829 | $0.50 | $0.5068 | 431.79K |
| Sep 2, 2026 | $0.59 | $0.6056 | $0.549 | $0.5525 | 375.61K |
| Sep 1, 2026 | $0.6204 | $0.63 | $0.59 | $0.6056 | 292.7K |
| Aug 31, 2026 | $0.66 | $0.6789 | $0.5901 | $0.6324 | 648.16K |
| Aug 28, 2026 | $0.6972 | $0.7274 | $0.68 | $0.721 | 744.47K |
| Aug 27, 2026 | $0.6333 | $0.8771 | $0.6176 | $0.717 | 3.85M |
| Aug 26, 2026 | $0.63 | $0.65 | $0.6175 | $0.6301 | 274.31K |
| Aug 25, 2026 | $0.7039 | $0.7039 | $0.6156 | $0.6419 | 734.15K |
| Aug 24, 2026 | $0.7152 | $0.74 | $0.6692 | $0.6863 | 2.22M |
| Aug 21, 2026 | $0.6294 | $0.659 | $0.6125 | $0.6456 | 645.48K |
| Aug 20, 2026 | $0.611 | $0.6449 | $0.5958 | $0.602 | 741.57K |
| Aug 19, 2026 | $0.6177 | $0.6686 | $0.59 | $0.5947 | 12.4M |
| Aug 18, 2026 | $0.6517 | $0.6706 | $0.63 | $0.6505 | 304.32K |
| Aug 17, 2026 | $0.74 | $0.7779 | $0.655 | $0.655 | 206.77K |
Latest GOVX news
The latest Smart Investors Daily articles mentioning GOVX.
Stock researchCompany · Overview
GOVX research
Overview
Company profile and research snapshot.
Company profile
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 16, 2026 | D. Boral Capital | Hold | — |
| Feb 19, 2026 | D. Boral Capital | Hold | — |
| Jan 21, 2026 | D. Boral Capital | Buy | — |
| Nov 19, 2025 | D. Boral Capital | Buy | — |
| Sep 26, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 18, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · Feb 13, 2026
12 Health Care Stocks Moving In Friday's Intraday Session
seekingalpha.com · Nov 13, 2025
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
